For Healthcare Professionals Outside the US
Blocking MEK in addition to BRAF is thought to:
Reduce the risk of treatment resistance1
Improve response rates over monotherapy3
The only combination approved to target
the BRAF V600 mutation in NSCLC2
References: 1. Nguyen-Ngoc T, Bouchaab H, Adjei AA, Peters S. BRAF alterations as therapeutic targets in non–small-cell lung cancer. J Thorac Oncol. 2015;10(10):1396-1403. 2. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 3. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug Healthc Patient Saf. 2014;6:77-88.